A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users

Genetics in Medicine

Volumn 17, Issue 1, 2015, Pages 3-11

  Osnabrugge, Ruben L ^a   Head, Stuart J ^a   Zijlstra, Felix ^a   Ten Berg, Jurriën M ^b   Hunink, Myriam G ^a,c   Kappetein, A Pieter ^a   Janssens, A Cecile J W ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

antiplatelet drugs; coronary artery disease; meta analyses; methodology; pharmacogenomics

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ALLELE; DRUG EFFICACY; DRUG USE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; LOSS OF FUNCTION MUTATION; META ANALYSIS; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; STENT THROMBOSIS; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; CORONARY ARTERY DISEASE; GENETICS; PHARMACOGENETICS; PUBLISHING; TREATMENT OUTCOME;

ALLELES; CORONARY ARTERY DISEASE; CYTOCHROME P-450 CYP2C19; GENOTYPE; HUMANS; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; PUBLICATION BIAS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84920520307     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2014.76     Document Type: Review

References (58)

1. IMS Institute for Healthcare Informatics. IMS Top 20 Global Products 2012. http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top-Line%20Market%20Data%20&%20Trends/Top-20-Global-Products-2012-2.pdf. Accessed 23 August 2013.
2. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78-e140.
3. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108:2244-2247.
4. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm#AIHP. Accessed 25 April 2014.
5. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011;343:d4588.
6. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306:2704-2714.
7. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19∗2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010;56:134-143.
8. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010;304:1821-1830.
9. Jadad AR, Cook DJ, Browman GP. A guide to interpreting discordant systematic reviews. CMAJ 1997;156:1411-1416.
10. Davidoff F, Haynes B, Sackett D, Smith R. Evidence based medicine. BMJ 1995;310:1085-1086.
11. Siontis KC, Hernandez-Boussard T, Ioannidis JP. Overlapping meta-analyses on the same topic: survey of published studies. BMJ 2013;347:f4501.
12. Osnabrugge RL, Capodanno D, Cummins P, Kappetein P, Serruys PW. Review and recommendations on the current practice of meta-analyses: a guide to appraise the evidence. EuroIntervention 2014;9:1013-1020.
13. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6: e1000100.
14. Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking metaanalyses In: Higgins JP and Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. John Wiley & Sons, Chichester, UK. 2008:243-296.
15. Guyatt GH, Oxman AD, Kunz R, et al.; GRADE Working Group. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol 2011;64:1294-1302.
16. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence-publication bias. J Clin Epidemiol 2011;64:1277-1282.
17. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:10.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
19. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990;263:1385-1389.
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
21. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006;25:3443-3457.
22. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 2001;323:101-105.
23. Cutlip DE, Windecker S, Mehran R, et al.; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351.
24. Liu YP, Hao PP, Zhang MX, et al. Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated metaanalysis. Thromb Res 2011;128:593-594.
25. Zabalza M, Subirana I, Sala J, et al. Meta-analyses of the association between cytochrome CYP2C19 loss-and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012;98:100-108.
26. Jang JS, Cho KI, Jin HY, et al. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol 2012;110:502-508.
27. Singh M, Shah T, Adigopula S, et al. CYP2C19∗2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful? Indian Heart J 2012;64:341-352.
28. Jin B, Ni HC, Shen W, Li J, Shi HM, Li Y. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Mol Biol Rep 2011;38:1697-1702.
29. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19∗2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 2011;11:199-206.
30. Yamaguchi Y, Abe T, Sato Y, Matsubara Y, Moriki T, Murata M. Effects of VerifyNow P2Y12 test and CYP2C19∗2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis. Platelets 2013;24:352-361.
31. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000.
32. Erik von E, Douglas GA, Matthias E, Stuart JP, Peter CG, Jan PV. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806-808.
33. Little J, Higgins JP, Ioannidis JP, et al. STrengthening the REporting of Genetic Association studies (STREGA)-an extension of the STROBE statement. Eur J Clin Invest 2009;39:247-266.
34. Bouman HJ, Harmsze AM, van Werkum JW, et al. Variability in on-treatment platelet reactivity explained by CYP2C19∗2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart 2011;97:1239-1244.
35. Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011;57:2474-2483.
36. Małek LA, Przyłuski J, Spiewak M, et al. Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. Cardiology 2010;117:81-87.
37. Ono T, Kaikita K, Hokimoto S, et al. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. Thromb Res 2011;128:e130-e136.
38. Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010;363:1704-1714.
39. Tiroch KA, Sibbing D, Koch W, et al. Protective effect of the CYP2C19 ∗17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 2010;160:506-512.
40. Yamamoto K, Hokimoto S, Chitose T, et al. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol 2011;57:194-201.
41. Malek LA, Kisiel B, Spiewak M, et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 2008;72:1165-1169.
42. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-317.
43. Jeong YH, Tantry US, Kim IS, et al. Effect of CYP2C19∗2 and ∗3 loss-offunction alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv 2011;4:585-594.
44. Simon T, Verstuyft C, Mary-Krause M, et al.; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375.
45. van Werkum JW, Heestermans AA, de Korte FI, et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation 2009;119:828-834.
46. Bebia Z, Buch SC, Wilson JW, et al. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 2004;76:618-627.
47. Gurbel PA, Nolin TD, Tantry US. Clopidogrel efficacy and cigarette smoking status. JAMA 2012;307:2495-2496.
48. Gurbel PA, Bliden KP, Logan DK, et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol 2013;62:505-512.
49. Osnabrugge RL, Kappetein AP, Janssens AC. Carriage of reduced-function CYP2C19 allele among patients treated with clopidogrel. JAMA 2011;305:467-468; author reply 468.
50. Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002;7:51-61.
51. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.
52. Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 2008;37: 120-132.
53. Moher D. The problem of duplicate systematic reviews. BMJ 2013;347:f5040.
54. Collet JP, Cuisset T, Rangé G, et al.; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-2109.
55. Gurbel PA, Erlinge D, Ohman EM, et al.; TRILOGY ACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 2012;308:1785-1794.
56. Price MJ, Berger PB, Teirstein PS, et al.; GRAVITAS Investigators. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-1105.
57. Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012;379:1705-1711.
58. Medscape. ARCTIC-GENE Throws Cold Water on Genotype-Guided Antiplatelet Therapy at PCI. http://www.medscape.com/viewarticle/810441. Accessed 1 November 2013.